Free Trial

Exelixis (EXEL) Competitors

$20.41
-0.59 (-2.81%)
(As of 05:17 PM ET)

EXEL vs. HALO, RGEN, NVAX, CRL, NRC, MEDP, PGEN, LUNA, NBIX, and RVMD

Should you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Halozyme Therapeutics (HALO), Repligen (RGEN), Novavax (NVAX), Charles River Laboratories International (CRL), National Research (NRC), Medpace (MEDP), Precigen (PGEN), Luna Innovations (LUNA), Neurocrine Biosciences (NBIX), and Revolution Medicines (RVMD).

Exelixis vs.

Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk.

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 2.4% of Halozyme Therapeutics shares are held by insiders. Comparatively, 2.9% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Halozyme Therapeutics has a net margin of 36.94% compared to Halozyme Therapeutics' net margin of 11.10%. Exelixis' return on equity of 225.71% beat Halozyme Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics36.94% 225.71% 20.52%
Exelixis 11.10%8.85%6.91%

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Exelixis. MarketBeat recorded 14 mentions for Halozyme Therapeutics and 11 mentions for Exelixis. Exelixis' average media sentiment score of 1.05 beat Halozyme Therapeutics' score of 0.50 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
8 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Exelixis
7 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Halozyme Therapeutics has higher earnings, but lower revenue than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$829.25M6.98$281.59M$2.4218.79
Exelixis$1.83B3.48$207.76M$0.6432.81

Halozyme Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Exelixis received 74 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.19% of users gave Halozyme Therapeutics an outperform vote while only 68.12% of users gave Exelixis an outperform vote.

CompanyUnderperformOutperform
Halozyme TherapeuticsOutperform Votes
503
69.19%
Underperform Votes
224
30.81%
ExelixisOutperform Votes
577
68.12%
Underperform Votes
270
31.88%

Halozyme Therapeutics currently has a consensus target price of $53.14, indicating a potential upside of 16.85%. Exelixis has a consensus target price of $26.13, indicating a potential upside of 24.40%. Given Halozyme Therapeutics' higher possible upside, analysts plainly believe Exelixis is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Exelixis
0 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.59

Summary

Halozyme Therapeutics beats Exelixis on 12 of the 18 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EXEL vs. The Competition

MetricExelixisBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$6.37B$262.53M$5.12B$8.03B
Dividend YieldN/A3.42%2.80%3.92%
P/E Ratio32.81244.19132.5815.24
Price / Sales3.4816,155.692,511.8172.17
Price / Cash27.3511.5035.6932.25
Price / Book2.996.435.404.58
Net Income$207.76M-$31.25M$105.63M$214.11M
7 Day Performance-1.08%0.81%-0.65%-0.01%
1 Month Performance-9.83%4.84%3.42%3.96%
1 Year Performance8.64%5.82%5.74%8.02%

Exelixis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HALO
Halozyme Therapeutics
4.6736 of 5 stars
$43.82
+0.5%
$53.14
+21.3%
+29.9%$5.58B$829.25M18.11373Analyst Forecast
Insider Selling
RGEN
Repligen
3.9963 of 5 stars
$172.48
+5.6%
$197.75
+14.7%
-1.0%$9.64B$638.76M689.951,783Insider Selling
Analyst Revision
News Coverage
NVAX
Novavax
3.8569 of 5 stars
$13.48
+2.8%
$14.00
+3.9%
+108.2%$1.89B$983.71M-4.251,543Analyst Forecast
Options Volume
Gap Up
High Trading Volume
CRL
Charles River Laboratories International
4.5291 of 5 stars
$232.82
+1.9%
$255.27
+9.6%
+8.8%$11.99B$4.13B27.3921,800Positive News
NRC
National Research
0 of 5 stars
$31.29
+6.0%
N/A-28.9%$704.41M$148.58M25.23435Positive News
MEDP
Medpace
4.8796 of 5 stars
$398.52
+2.4%
$443.00
+11.2%
+86.0%$12.35B$1.96B40.625,900Positive News
PGEN
Precigen
4.1647 of 5 stars
$1.37
+1.5%
$10.00
+629.9%
+5.3%$341.02M$6.22M-3.51202Analyst Upgrade
LUNA
Luna Innovations
0.988 of 5 stars
$2.81
+2.9%
$10.00
+255.9%
-63.1%$95.43M$116.61M-35.13337Upcoming Earnings
NBIX
Neurocrine Biosciences
4.7318 of 5 stars
$138.48
+1.7%
$148.96
+7.6%
+49.1%$13.94B$1.89B38.151,400Insider Selling
RVMD
Revolution Medicines
3.794 of 5 stars
$37.38
+0.6%
$43.20
+15.6%
+49.0%$6.13B$4.57M-9.97378News Coverage

Related Companies and Tools

This page (NASDAQ:EXEL) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners